Traffic Alert: Texas Medical Center road closures/water and sewer repairs. Please plan ahead and use alternate routes when possible. Learn more >

Ericka P. Greene, MD

The Sumner Family Distinguished Chair in Neuromuscular Research, Stanley H. Appel Department of Neurology
Professor of Clinical Neurology, Academic Institute
Full Clinical Member, Research Institute
Program Director, Neurology Residency and Neuromuscular Medicine Residency, Stanley H. Appel Department of Neurology
Houston Methodist
Weill Cornell Medical College

Research Lab


While completing her postdoctoral training, Dr. Greene studied under the renowned Dr. Stanley Appel, the former chair of the Department of Neurology at Houston Methodist Hospital and the founder of the Houston Methodist Neurological Institute. After completion of a fellowship in Dr. Appel’s laboratory, she became a tenure track Associate Professor of Neurology at the Baylor College of Medicine in Houston, Texas. Dr. Greene is a member of the American Academy of Neurology, the American Board of Psychiatry and Neurology, and a recipient of the Robert Wood Johnson Foundation’s Minority Medical Faculty Development Program. She joined the Houston Methodist Specialty Physician Group in 2005.

Description of Research

Dr. Greene's research aims to characterize the peripheral immune inflammatory response in ALS and other neurodegenerative diseases, and identify the potential markers that may reflect disease activity and progression. Her translational research seeks to identify and develop effective therapies that positively alter the natural progression of these diseases, including Myotonic Dystrophy, myasthenia gravis, and chronic inflammatory polyneuropathies. 

Areas Of Expertise

Stem cells ALS Neurology Biomarkers Dendritic cells MCP-1 Microglia
Education & Training

Residency, Baylor College of Medicine
Internship, Baylor College of Medicine
MD, University of Texas at Houston Medical School
Research Fellowship, Baylor College of Medicine

Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial
Thornton, CA, Moxley, RT, Eichinger, K, Heatwole, C, Mignon, L, Arnold, WD, Ashizawa, T, Day, JW, Dent, G, Tanner, MK, Duong, T, Greene, EP, Herbelin, L, Johnson, NE, King, W, Kissel, JT, Leung, DG, Lott, DJ, Norris, DA, Pucillo, EM, Schell, W, Statland, JM, Stinson, N, Subramony, SH, Xia, S, Bishop, KM & Bennett, CF 2023, , The Lancet Neurology, vol. 22, no. 3, pp. 218-228.

Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development
for the Healey ALS Platform Trial Study Group, HEALEY ALS Platform Trial Study Group, Biostatisticians, Investigators, Clinical Operations Team & Medical Monitors 2022, , Annals of Neurology, vol. 91, no. 2, pp. 165-175.

Neurologic Therapeutics in 2035: The Neurology Future Forecasting Series
Johnson, NE & Greene, E 2021, , Neurology, vol. 97, no. 24, pp. 1121-1127.

Neurogenic orthostatic hypotension: A common complication of successful pancreas transplantation
Kuten, SA, Graviss, EA, Nguyen, DT, Gaber, AO, Sadhu, AR, Simpson, EP, Yi, SG, Podder, H, Kagan, A & Knight, RJ 2021, , Transplantation Direct, vol. 7, no. 12, e795, pp. e795.

Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement
the Ethics, Law, and Humanities Committee (a joint committee of the AAN, ANA, and CNS) 2022, , Neurology, vol. 98, no. 4, pp. 154-159.

Contemporary Neuroscience Core Curriculum for Medical Schools
The AAN Undergraduate Education Subcommittee (UES) & The AAN Education Committee 2021, , Neurology, vol. 97, no. 14, pp. 675-684.

Fast progression in amyotrophic lateral sclerosis is associated with greater tdp-43 burden in spinal cord
Cathcart, SJ, Appel, SH, Peterson, LE, Greene, EP, Powell, SZ, Arumanayagam, AS, Rivera, AL & Cykowski, MD 2021, , Journal of Neuropathology and Experimental Neurology, vol. 80, no. 8, pp. 754-763.

Spinal cord and motor neuron TDP-43 pathology in a sporadic inclusion body myositis patient
Cathcart, SJ, Greene, EP, Powell, SZ, Arumanayagam, AS, Rivera, AL, Tawil, R, Appel, SH & Cykowski, MD 2021, , Journal of Neuropathology and Experimental Neurology, vol. 79, no. 10, pp. 1130-1133.

Multifocal Noninvasive Magnetic Stimulation of the Primary Motor Cortex in Type 1 Myotonic Dystrophy -A Proof of Concept Pilot Study
Greene, E, Thonhoff, J, John, BS, Rosenfield, DB & Helekar, SA 2021, , Journal of neuromuscular diseases, vol. 8, no. 6, pp. 963-972.

Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review
Lewis, RA, Cornblath, DR, Hartung, HP, Sobue, G, Lawo, JP, Mielke, O, Durn, BL, Bril, V, Merkies, ISJ, Bassett, P, Cleasby, A, van Schaik, IN, Sabet, A, George, K, Roberts, L, Carne, R, Blum, S, Henderson, R, Van Damme, P, Demeestere, J, Larue, S, D’Amour, C, Kunc, P, Valis, M, Sussova, J, Kalous, T, Talab, R, Bednar, M, Toomsoo, T, Rubanovits, I, Gross-Paju, K, Sorro, U, Saarela, M, Auranen, M, Pouget, J, Attarian, S, Le Masson, G, Wielanek, A, Desnuelle, C, Delmon, E, Clavelou, P, Aufauvre, D, Schmidt, J, Zschuentzsch, J, Sommer, C, Kramer, D, Hoffmann, O, Goerlitz, C, Haas, J, Chatzopoulos, M, Yoon, R, Gold, R, Berlit, P, Jaspert-Grehl, A, Liebetanz, D, Kutschenko, A, Stangel, M, Trebst, C, Baum, P, Bergh, F, Klehmet, J, Meisel, A, Klostermann, F, Oechtering, J, Lehmann, H, Schroeter, M, Hagenacker, T, Mueller, D, Sperfeld, A, Bethke, F, Drory, IV, Algom, A, Yarnitsky, D, Murinson, B, Di Muzio, A, Ciccocioppo, F, Sorbi, S, Mata, S, Schenone, A, Grandis, M, Lauria, G, Cazzato, D, Antonini, G, Morino, S, Cocito, D, Zibetti, M, Yokota, T, Ohkubo, T, Kanda, T, Kawai, M, Kaida, K, Onoue, H, Kuwabara, S, Mori, M, Iijima, M, Ohyama, K, Baba, M, Tomiyama, M, Nishiyama, K, Akutsu, T, Yokoyama, K, Kanai, K, van Schaik, IN, Eftimov, F, Notermans, NC, Visser, N, Faber, C, Hoeijmakers, J, Rejdak, K, Chyrchel-Paszkiewicz, U, Casanovas Pons, C, Antonia, M, Gamez, J, Salvado, M, Infante, CM, Benitez, S, Lunn, M, Morrow, J, Gosal, D, Lavin, T, Melamed, I, Testori, A, Ajroud-Driss, S, Menichella, D, Simpson, E, Lai, ECH, Dimachkie, M, Barohn, RJ, Beydoun, S, Johl, H, Lange, D, Shtilbans, A, Muley, S, Ladha, S, Freimer, M, Kissel, J, Latov, N, Chin, R, Ubogu, E, Mumfrey, S, Rao, T, MacDonald, P, Sharma, K, Gonzalez, G, Allen, J, Walk, D, Hobson-Webb, L & Gable, K 2020, , Journal of the Peripheral Nervous System, vol. 25, no. 3, pp. 230-237.

Immune-Mediated Neuropathies
Fadia, M, Shroff, S & Simpson, E 2019, , Current Treatment Options in Neurology, vol. 21, no. 6, 28.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
on Behalf of the PRIMA Trial Investigators and the PATH Study Group 2019, , Journal of the Peripheral Nervous System, vol. 24, no. 1, pp. 48-55.

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study
on behalf of the PATH study group 2019, , Journal of the Peripheral Nervous System, vol. 24, no. 1, pp. 72-79.

Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial
The Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium 2019, , Muscle and Nerve, vol. 59, no. 2, pp. 201-207.

Consensus-based care recommendations for adults with myotonic dystrophy type 1
Ashizawa, T, Gagnon, C, Groh, WJ, Gutmann, L, Johnson, NE, Meola, G, Moxley, R, Pandya, S, Rogers, MT, Simpson, E, Angeard, N, Bassez, G, Berggren, KN, Bhakta, D, Bozzali, M, Broderick, A, Byrne, JLB, Campbell, C, Cup, E, Day, JW, De Mattia, E, Duboc, D, Duong, T, Eichinger, K, Ekstrom, AB, Van Engelen, B, Esparis, B, Eymard, B, Ferschl, M, Gadalla, SM, Gallais, B, Goodglick, T, Heatwole, C, Hilbert, J, Holland, V, Kierkegaard, M, Koopman, WJ, Lane, K, Maas, D, Mankodi, A, Mathews, KD, Monckton, DG, Moser, D, Nazarian, S, Nguyen, L, Nopoulos, P, Petty, R, Phetteplace, J, Puymirat, J, Raman, S, Richer, L, Roma, E, Sampson, J, Sansone, V, Schoser, B, Sterling, L, Statland, J, Subramony, SH, Tian, C, Trujillo, C, Tomaselli, G, Turner, C, Verma, A, White, M & Winblad, S 2018, , Neurology: Clinical Practice, vol. 8, no. 6, pp. 507-520.

Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis
Thonhoff, JR, Simpson, EP & Appel, SH 2018, , Current opinion in neurology, vol. 31, no. 5, pp. 635-639.

Expanded autologous regulatory T-lymphocyte infusions in ALS A phase I, first-in-human study
Thonhoff, JR, Beers, DR, Zhao, W, Pleitez, M, Simpson, EP, Berry, JD, Cudkowicz, ME & Appel, SH 2018, , Neurology: Neuroimmunology and NeuroInflammation, vol. 5, no. 4, e465, pp. e465.

Expanded autologous regulatory T-lymphocyte infusions in ALS
Thonhoff, JR, Beers, DR, Zhao, W, Pleitez, M, Simpson, EP, Berry, JD, Cudkowicz, ME & Appel, SH 2018, , Neurology - Neuroimmunology Neuroinflammation, vol. 5, no. 4. <>

Intravenous versus subcutaneous immunoglobulin – Authors' reply
PATH study group 2018, , The Lancet Neurology, vol. 17, no. 5, pp. 393-394.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
ITALSGEN Consortium, Genomic Translation for ALS Care (GTAC) Consortium, ALS Sequencing Consortium, NYGC ALS Consortium, Answer ALS Foundation, Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, SLAGEN Consortium, French ALS Consortium & Project MinE ALS Sequencing Consortium 2018, , Neuron, vol. 97, no. 6, pp. 1268-1283.e6.